Stock Financial Ratios, Dividends, Split History
KRP / Kimbell Royalty Partners, LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||390.57|
|Enterprise Value ($M)||389.46|
|Book Value ($M)||203.85|
|Book Value / Share||12.11|
|Price / Book||1.92|
|NCAV / Share||-1.16|
|Price / NCAV||-20.24|
|Common Shares Outstanding||16,836,453|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||n/a|
|Return on Assets (ROA)||n/a|
|Return on Equity (ROE)||n/a|
|Income Statement (mra) ($M)|
|Accrued Revenue Processing Fees Current||344,314.00|
|Results Of Operations Revenue From Oil And Gas Producing Activities||0.00|
|Cash Flow Statement (mra) ($M)|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1657788|
Stock splits are used by Kimbell Royalty Partners, LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
4h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
Related News Stories
Have you ever owned a royalty LP? Usually, there's a fixed amount of assets for which the LP gets paid royalty interests in a variety of ways, and a target termination date, usually with no growth. The reserves are just drawn down, and may or may not be replaced. (1-0)
The June MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers. (56-0)
Midstream and MLPs synched up this week to rally 2.7%, outperforming the S&P 500 and utilities, despite renewed oil price angst this week. Midstream stocks and MLPs resumed their recovery after last week's pause, and have now posted gains in 7 of the last 10 weeks. After bottoming in late March, the AMZ and AMEI have posted total returns of 16.2% and 12.3%, respectively. The rally has helped the MLP Index break back into positive territory year-to-date, and the MLP Index closed the week almost exactly at its 200-day moving average (269. (62-0)
Kimbell Royalty Partners, LP (NYSE:KRP) Acquisition of Haymaker Minerals & Royalties, LLC and Haymaker Resources, LP May 29, 2018 8:30 AM ET (37-0)
The following slide deck was published by Kimbell Royalty Partners LP in conjunction with this event. (9-0)
as of ET